Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU83KP)

Drug Name
1-((S)-2-aminopropyl)-1H-indazol-6-ol Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
135453290
CAS Number
CAS 210580-75-9
TTD Drug ID
DMU83KP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [3]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [4]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [5]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [6]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [7]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [8]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [9]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [10]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [12]
Eletriptan DMW649X Migraine 8A80 Approved [13]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [13]
Frovatriptan DM7RE8P Migraine 8A80 Approved [13]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [14]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [15]
Almogran DM7I64Z Migraine 8A80 Approved [16]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [17]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [18]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [20]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [21]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [22]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [23]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [24]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [18]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [25]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [26]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [28]
Triflupromazine DMKFQJP Nausea MD90 Approved [29]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [30]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [31]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [32]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [33]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [34]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [34]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [34]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [28]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [35]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [36]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [37]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [38]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [39]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [40]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [41]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [42]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 4 receptor (HTR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [44]
Tegaserod DM3XYD1 Irritable bowel syndrome DD91.0 Approved [45]
R0-93877 DMM4U9G Constipation DD91.1 Approved [14]
HTF 919 DM78G6F Constipation DD91.1 Approved [46]
Mosapride DM2VOQ3 N. A. N. A. Phase 4 [47]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [48]
Lintopride DMSHGWN Nausea MD90 Phase 2 [49]
TD-8954 DM3C9NV Gastrointestinal disease DE2Z Phase 2 [50]
SB-207266A DM27KFY Irritable bowel syndrome DD91.0 Phase 2 [14]
YKP-GI DM740LV Constipation DD91.1 Phase 2 [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [13]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [52]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [53]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [54]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [37]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [55]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [56]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [57]
Treximet DMU54QB Migraine 8A80 Approved [58]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [28]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [60]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [61]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [62]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [63]
Methysergide DM1EF73 Migraine 8A80 Approved [64]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [65]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [66]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [67]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [32]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [1]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [1]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [1]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Inhibitor [1]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Inhibitor [1]
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [1]

References

1 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
2 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
3 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
5 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
6 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
7 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
8 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
9 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
10 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
11 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
12 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
15 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
16 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
17 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Company report (NeurAxon)
20 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
21 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
22 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
23 Clinical pipeline report, company report or official report of Klus Pharma
24 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
25 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
26 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
27 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
28 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
29 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
30 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
31 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
32 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
33 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
34 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
35 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
36 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
37 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
38 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
39 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
40 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
41 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
42 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
43 Clinical pipeline report, company report or official report of Lundbeck.
44 Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
45 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
46 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
47 The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
48 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
49 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
50 The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
51 A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
52 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
53 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
54 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
55 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
56 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
57 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
58 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
60 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
61 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
62 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
63 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
64 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
65 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
66 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
67 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.